Embla Medical

	17/10 14:37 af ProInvestorNEWS	Velkommen til Embla Medical chat.
	17/10 14:54 af ProInvestorNEWS	Q2 2024 Recent Embla Medical corporate deck (July 23, 2024) Roadshow presentation: (link)
	17/10 14:55 af ProInvestorNEWS	Q2 2024 Report 2024 (July 23, 2024) (link)
	17/10 14:57 af ProInvestorNEWS	Why is Embla an attractive case right now? US Medicare implemented extended coverage in September 2024 Coverage expansion will allow less mobile/low-active amputees (K2 patients) access to advanced bionic devices (previously restricted to K3/K4). The new reform is expected to contribute meaningfully to Embla's organic growth over the next 3-5 years
	17/10 14:57 af ProInvestorNEWS	Strong growth case with increasing Earnings and solid cash flow generation Since listing in 1999 the business has grown at ~17% CAGR driven by organic sales and acquisitions ~85% of EBIT converted into FCF in the past decade. For 2024 the Company is guiding 6-8% organic growth and ~20% EBITDA (22% in Q2 2024; up 3pp vs Q3 2023).
	17/10 14:58 af ProInvestorNEWS	Growth'27: Late March 2023, Embla Medical launched a new five-year growth ambition of 7-10% average growth (organic growth of 5-7% and M&A of 2-3%).
	17/10 14:58 af ProInvestorNEWS	Innovation agenda 5% of revenue (USD ~30m) is invested in R&D annually with product launches every year. 70-80% of sales in prosthetics is reoccuring as the replacement cyle typically runs for 3-4 years. Two new bionic knee solutions (NAVII and ICON) were launched end of Q2 2024.
	17/10 14:58 af ProInvestorNEWS	Neuro Orthotics Back in January this year Embla acquired a German Neuro Orthotic Business Fior & Gentz for EUR 100m. F&G develops and manufacture "technical orthotics" (bionic joints) for patients suffering from disabled mobility following e.g. stroke, MS, CP. Neuro Orthotics is perhaps 10-20 years after prosthetics in terms of awareness and reimbursement but with great growth potential.
	17/10 14:59 af ProInvestorNEWS	The business recorded USD 23m in sales in 2023 (mainly Germany) and Embla will utilize its commercial footprint to expand the business globally. F&G is accretive.
	17/10 15:00 af ProInvestorNEWS	Kilde: Klaus Sindahl Head of Investor Relations Embla-Medical
	17/10 15:01 af ProInvestorNEWS	Webcast på dansk fra Økonomisk Ugebrev (link)
	17/10 15:02 af ProInvestorNEWS	OBS: Embla Medical har en betalt digital IR-aftale med ProInvestor.com
	21/10 05:56 af ProInvestorNEWS	Børsen: Embla Medicals ser vækstmulighed i forbedret tilskudssituation i USA. Flere får adgang til avancerede proteser, og det kan sikre Embla Medicals vækst næste år. (Side 10)
	21/10 07:39 af ProInvestorNEWS	Medwatch: (link)
	21/10 07:42 af ProInvestorNEWS	Børsen: Corona satte dybe spor i Demant-ejers islandske børsselskab: Lysning i USA kan vende billedet Flere får adgang til avancerede proteser i USA. Det kan sikre Embla Medical et løft i væksten næste år (link)
	21/10 07:46 af B.Andersen	Mon ikke omtalen sætter skub i kursen i dag?
	21/10 08:05 af ProInvestorNEWS	i dag kl. 08:00 ∙ MarketWire Proteseselskabet Embla Medicals ser vækstmulighed i forbedret tilskudssituation i USA. Flere får adgang til avancerede proteser, og det kan sikre Embla Medicals vækstløft næste år. Det skriver Børsen. For islandske Embla Medical kan der være et vækstløft på vej. En ny tilskudsordning i USA fra det offentlige amerikanske sundhedsprogram Medicare betyder, at flere amerikanere snart kan få tilskud til de mere avancerede bionik-proteser.
	21/10 08:05 af ProInvestorNEWS	Det må formodes, at Embla Medical i de kommende kvartaler vil nyde godt af denne ændring i adgangen til de mere avancerede og dyre produkter i USA, vurderer Niels Granholm-Leth, der er aktieanalysechef i investeringsbanken Carnegie, over for Børsen
	21/10 08:05 af ProInvestorNEWS	Bionik-proteser er både dyrere og mere lønsomme end de mekaniske proteser. Hvor en bionik-protese, som har indbygget batteri, computer og en motor, i dag koster omkring 10.000-20.000 dollar, koster en mekanisk knæprotese derimod 2000-4000 dollar.
	21/10 08:06 af ProInvestorNEWS	Der kommer en opgraderingscyklus, men det kommer til at ske gradvist, siger Sveinn Sölvason, der er administrerende direktør i Embla Medicals, og som indtil videre holder fast i vækstmålene. Originalartikel: Børsen, 21. oktober, side 10
	21/10 08:08 af Stroka	+3,25% i åbning.
	21/10 10:44 af HanneP	Spændende virksomhed. Bionik-teknologien er helt enestående i forhold til de gammeldags mekaniske proteser.
	22/10 07:05 af ProInvestorNEWS	Interim report Q3 2024 22 October 2024 Sveinn Sölvason, President and CEO, comments: “We delivered solid sales in the third quarter amounting to USD 214 million. Organic sales growth was 7% and local currency growth was 11%. The strong momentum we have seen in EMEA throughout 2024 continued driven by strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was more modest for the quarter
	22/10 07:05 af ProInvestorNEWS	As of September 1, 2024, US Medicare has expanded access to advanced bionics for K2 patients. Healthcare professionals are currently assessing first patients as part of the replacement cycle through medical documentation that a bionic knee would improve the patient’s functional health outcomes.

	22/10 07:05 af ProInvestorNEWS	Our EBITDA margin came in strong for the quarter at 22%. We continue to see the positive effects from the cost reduction initiatives implemented in manufacturing earlier this year as well as contribution from better product mix and cost control. We are executing well on our Growth’27 strategy and reiterate our full year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items.”
	22/10 07:06 af ProInvestorNEWS	Highlights Q3 2024 Sales amounted to USD 214 million and organic growth was 7%, compared to 7% in Q3 2023. In local currency sales growth was 10% increase including acquisitions and 11% reported growth (USD growth). Prosthetics & Neuro Orthotics sales grew by 9%, Patient Care grew 9%, while Bracing & Supports grew by 1% (all organically). EMEA continued to contribute strongly during Q3, whereas performance in Americas remained soft. APAC delivered good growth.
	22/10 07:06 af ProInvestorNEWS	Gross profit margin was 63%, compared to 62% in Q3 2023. The increase in gross profit can partly be ascribed to cost reduction initiatives in manufacturing implemented during Q1 as well as better product mix and manufacturing efficiency. EBITDA amounted to USD 47 million, and EBITDA margin was 22% of sales, compared to 19% in Q3 2023. Increasing gross profit margin and continued cost control contributed to increased profitability
	22/10 07:07 af ProInvestorNEWS	Net profit grew by 58% and was USD 22 million with a net profit margin of 10%, compared to 7% of sales in Q3 2023. Cash generated from operations amounted to USD 52 million or 24% of sales, compared to 17% of sales in Q3 2023. Free cash flow amounted to USD 33 million or 15% of sales, compared to 9% of sales in Q3 2023. Free cash flow was strong in the third quarter with solid operating results. NIBD/EBITDA before special items was 2.8x at the end of Q3 2024. Share buybacks continue to be pause
	22/10 07:08 af ProInvestorNEWS	Other highlights During the third quarter we introduced the third generation of our Naked Prosthetics finger device portfolio, while our newly launched bionic knee solutions, NAVii® by Össur and Icon® by College Park continue to be rolled out in selected markets as part of our limited launch program. A full launch of NAVii and Icon is expected early 2025, as previously announced.
	22/10 07:08 af ProInvestorNEWS	A global team of elite para-athletes who wear Össur’s renowned prosthetics won 22 medals and set five new Paralympic Records during the 2024 Paralympic Games in Paris, with the company’s iconic carbon fiber Cheetah sports blades, easily identifiable by their distinctive yellow stripe, dominating several categories of Athletics competition
	22/10 07:09 af ProInvestorNEWS	2024 outlook We reiterate our full year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items.
	22/10 07:09 af ProInvestorNEWS	Læs hele meddelelsen: (link)
	22/10 07:13 af ProInvestorNEWS	Medwatch: Embla Medical vokser encifret i tredje kvartal Den islandske proteseproducent kan se frem til udvidet dækning i USA. (link)
	22/10 07:14 af ProInvestorNEWS	Embla Medical ser frem mod udvidet dækning i USA efter stærkt tredje kvartal (link)
	22/10 07:34 af B.Andersen	Et stærkt regnskab helt som forventet.
	22/10 07:36 af B.Andersen	Positivt med fremgang på alle markeder.
	22/10 07:43 af Stroka	Turnarounden efter nogle dårlige år må siges at være mere end godkendt. :-)
	22/10 07:45 af Stroka	Konference call: (link)
	22/10 07:47 af Stroka	To actively participate in the Q&A session of the call please use following link for dial in options (link)
	23/10 08:18 af ProInvestorNEWS	Embla Medical får hævet kursmålet til 41 kr. fra 36,40 kr. hos Nordea (link)
	23/10 08:20 af ProInvestorNEWS	HCAs event i dag - Embla Medical – Presentation of Interim report Q3 2024 (link)
	24/10 06:09 af ProInvestorNEWS	Embla Medical – Recording of Q3 2024 result presentation (link)
	24/10 09:32 af BSinvest	Likviditeten er ikke særlig stor i Embla. Svært at samle en større portion op uden at aktien stiger for meget.
	24/10 09:44 af BSinvest	Handles på en p/e på 33,5. Det er vel et fair niveau med de kortsigtede vækstudsigter. Får bionik-proteserne for alvor et gennembrud vil kursen ryge gevaldigt i vejret. Det bliver spændende at følge.
	25/10 16:07 af ProInvestorNEWS	Selvom regnskabssæsonen ikke for alvor er gået i gang endnu, er der endnu en gang besøgsrekord på ProInvestor.com. Tak for at følge med! I denne pharma- og biotekopdatering kommer Helge Larsen ind på fedmesektoren, bl.a. et nyt studie fra Novo, hvor glp1 i Ozempic kan have en positiv effekt på alzheimers. Slutteligt fortæller han om Embla Medical, som laver proteser, og hvor nyeste skud på stammen er udviklet med kunstig intelligens. Kort video (link)
	28/10 12:42 af ProInvestorNEWS	"Embla sikker havn ved rødt efterår på aktiemarkedet Embla Medicals 3. kvartalsregnskab bekræftede investorernes positive syn på selskabet og aktien. På kort sigt forstærkes det positive syn på aktien af, at kursen med en betaværdi på 0,17 er stort set immun overfor en generel nedtur på aktiemarkedet". Læs hele analysen fra Økonomisk Ugebrev i debatten: (link)
	29/10 06:15 af Helge Larsen/PI-redaktør	BSinvest..Bruno Japp fra ØU har den samme analyse og kursmål, som du på aktien. I er begge af den gamle skole. ;-)
	19/11 06:03 af Helge Larsen/PI-redaktør	Godmorgen :-)